STAMPEDE otherwise follows a line of randomized trials (e.g., MAST, TAXOMET, IMPROVE) that have failed to prove cancer ...

In a new consensus statement, the European Society of Cardiology has declared vaccinations for common infections to be a ...

AstraZeneca PLC closed 22.77% short of its 52-week high of £133.88, which the company achieved on September 3rd.

TMUS, AZN, and CMCSA each face market headwinds, but new analyst reports highlight strengths shaping their outlooks.

AstraZeneca AZN is one of the leading drugmakers in the oncology space. Oncology sales (comprising around 41% of AstraZeneca‘s total revenues) rose 13% in the first quarter of 2025, generating $5.6 ...

Despite a Q1 revenue miss due to currency headwinds, core EPS beat expectations for AstraZeneca. Read why AZN stock is a Buy.

Artelo gets Buy rating from Boral Capital after positive updates on ART27.13, ART26.12, and preclinical success of its ...

Artificial intelligence (AI) transforms oncology by enhancing decision-making, improving patient care, and streamlining ...

Dietary approaches are shaping up as a key aspect of chronic obstructive pulmonary disease (COPD) management.

US President Donald Trump has threatened to impose tariffs at a rate as high as 200pc on imported drugs on Tuesday night in ...

Imagine a world without disease. Sounds utopian? AI just made it a multibillion-dollar bet to discover drugs – and forget Big ...

Major new analysis from the Thrombotic Thrombocytopenia Syndrome (TTS) Consortium has provided critical insights into the ...